| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | BORAGEN INC | 5 LABORATORY DRI STE 2150 | DURHAM | NC | 27709 | DURHAM | USA | R43AI155112 | Benzoxaborole-based antimalarial drug discovery | 000 | 2 | NIH | 4/1/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | BORAGEN INC | 5 LABORATORY DRI STE 2150 | DURHAM | NC | 27709 | DURHAM | USA | R43AI155112 | Benzoxaborole-based antimalarial drug discovery | 000 | 2 | NIH | 10/14/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $299,639 ) |
| | 2021 | 2021 | BORAGEN INC | 5 LABORATORY DRI STE 2150 | DURHAM | NC | 27709 | DURHAM | USA | R43AI155112 | Benzoxaborole-based antimalarial drug discovery | 001 | 2 | NIH | 7/7/2021 | $299,639 |
| | 2021 | 2020 | BORAGEN INC | 5 LABORATORY DRI STE 2150 | DURHAM | NC | 27709 | DURHAM | USA | R43AI155112 | Benzoxaborole-based antimalarial drug discovery | 000 | 1 | NIH | 12/14/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $300,500 ) |
| | 2020 | 2020 | BORAGEN INC | 5 LABORATORY DRI STE 2150 | DURHAM | NC | 27709 | DURHAM | USA | R43AI155112 | Benzoxaborole-based antimalarial drug discovery | 000 | 1 | NIH | 7/8/2020 | $300,500 |
|
|
